Engraftment syndrome (ES) is increasingly observed in patients who receive auto-SCT. To investigate this fact, validate the clinical criteria for ES diagnosis and analyze the risk factors for this complication, we reviewed 328 consecutive peripheral blood auto-SCT performed during the past 7 years. A total of 43 patients presented with clinical or biological data suggestive of ES. Of the total, 41 (95%) and 22 (51%) could be diagnosed with ES using the Maiolino criteria (MC) and the Spitzer criteria (SC), respectively. The SC were less sensitive as they do not consider some relevant clinical data and limit the observation time after engraftment. All ES cases had high C-reactive protein (CRP) values not observed in the remaining patients at engraftment (median ± s.d.: 17.5 ± 7.3 vs 2.4 ± 3.4 mg per 100 ml; P ¼ 0.0001). Multivariate analysis showed a higher risk of ES in SCT performed in recent years (relative risk (RR) 2.3, 95% confidence interval (CI 1.0-4.7), female patients (RR 2.5, 95% CI 1.2-5.2), and absence of intensive chemotherapy before SCT (RR 8.8,). All patients except one improved after treatment with corticosteroids. The MC seem to be the best tool to establish a diagnosis of ES. In doubtful cases, the diagnosis could be confirmed by evaluating CRP. Auto-SCT in patients not receiving previous chemotherapy could explain the increasing incidence of ES in the past years.
Introduction
Engraftment syndrome (ES), 1 also known as autoaggression syndrome, 2 peri-engraftment respiratory distress syndrome 3 or aseptic shock syndrome, 4 is a poorly understood complication of hematopoietic SCT. The pathogenesis of ES is not well defined but probably involves the release of pro-inflammatory cytokines (IL-2, TNF-a, IFNg, IL-8 and IL-6), M-CSF, EPO, products of degranulation and oxidative metabolism of neutrophils and systemic endothelial damage. 4, 5 Although described in the 1990s, 1 this syndrome is being increasingly recognized over recent years. 6, 7 Despite occasionally reported after allo-SCT, ES is basically diagnosed in the context of auto-SCT. Clinical features of ES include combinations of non-infectious fever, skin rash mimicking acute GVHD, pulmonary infiltrates, hypoxia, diarrhea and other clinical manifestations reminiscent of capillary leak syndrome (weight gain, edema, ascites and hypoalbuminemia) occurring during the peri-engraftment period. 1, 5, 8 The incidence of this syndrome varies from 7 to 59% in different reports, reflecting the different diagnostic criteria applied. In 2001, Spitzer 4 proposed relatively complex clinical criteria based on the presence or absence of several major and minor symptoms and signs that developed within 96 h of engraftment (Table 1 ). In the same year, Cappizzi et al. 3 limited the diagnosis to patients with fever and pulmonary injury that occurred within 5 days of neutrophil engraftment. In 2003, Maiolino et al. 8 proposed a simpler classification that focused on non-neutropenic fever and one of the most frequent clinical signs commencing 24 h before or after the first appearance of neutrophils in the peripheral blood (Table 1) . Recently, Dispenzieri et al., 7 on the basis of their observations in patients who receive an auto-SCT for polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes (POEMS) syndrome, proposed maintaining the Spitzer and Maiolino clinical criteria but uncoupling the timing between clinical symptoms and neutrophil recovery.
The differential diagnosis between ES and other complications observed early after auto-SCT, especially infections that develop at the end of the neutropenic phase, can sometimes be complex. This has a special relevance because ES responds dramatically to corticosteroids when they are administered early after the beginning of symptoms. However, when incorrectly treated or when the treatment is delayed, ES can evolve to an irreversible multiple organ dysfunction syndrome. 4, 7 In this study we retrospectively analyzed clinical data from 328 consecutive peripheral blood auto-SCTs performed in our institution between 2001 and 2007 in an attempt to better characterize the clinical criteria for the diagnosis of ES, to analyze the suspected increasing incidence and to identify risk factors favoring this complication.
Patients and methods

Patients
The clinical charts of consecutive patients who received a peripheral blood auto-SCT between January 2001 and December 2007 were analyzed. Fifteen cases who received T-cell-depleted grafts for treating multiple sclerosis were excluded. 9 The remaining 328 patients were 182 males and 146 females, with a median age of 52 years (range 18-70). The patient, disease and transplantation characteristics are shown in Table 1 . In 89 cases (27%), the underlying disease was in the early phase of SCT (first complete response), in 86 (26%) in intermediate phase (partial response) and in 121 (37%) in the advanced phase. A total of 20 patients, all of whom were suffering from amyloidosis and POEMS syndrome, had never received chemotherapy before SCT and were mobilized with G-CSF alone.
PBSCs were obtained after mobilization with G-CSF (n ¼ 186, 57%) or chemotherapy and G-CSF (n ¼ 142, 43%). Almost all patients with a lymphoproliferative disease received BEAM or BEAC (BCNU 300 mg/m 2 , etoposide 800 or 1600 mg/m 
Method
To detect all cases with a possible ES, we analyzed all patients with a non-infectious fever developed within 7 days of engraftment (first day of ANC of 40.5 Â 10 9 /l on two consecutive days). In addition, we evaluated in the whole series the presence or absence of the remaining clinical manifestations and biological abnormalities reported in the Spitzer criteria (SC) and Majolino criteria (MC) ( Table 2) . Finally, we applied and compared both clinical diagnostic criteria.
Non-infectious fever was defined as a new fever (438 1C) without clinical or microbiological documentation or response to antimicrobials. Pulmonary infiltrates were documented using X-ray or computed tomography and were considered ES if there were no signs of infection, cardiac failure or pulmonary embolism. Skin rash was defined as maculo-papular exanthema mimicking acute GVHD involving 425% of body surface area. Weight gain was accepted when it was 42.5% of the basal. Diarrhea was defined as at least two episodes of liquid depositions per day without microbiological documentation of infection. Hepatic dysfunction was defined as either total bilirubin X2 mg per 100 ml or transaminase levels X2 times normal, and renal insufficiency as serum creatinine of X2 times normal. Transient encephalopathy was accepted 
ES treatment
All patients in whom ES was suspected received methylprednisolone at the dose of 1 mg/kg every 12 h. This treatment was started as soon as possible but always after stopping G-CSF, administering 24-48 h of broad-spectrum antibiotics and after confirming negativity of the microbiological tests. This dose was maintained for 3 days and then tapered over 7-8 days.
Statistical analysis
Descriptive statistical analysis was performed. To compare dichotomous variables, Fisher (two tailed) and w 2 tests were used. Logistic regression analysis was performed using the backward stepwise (Wald) method. All statistical studies were performed using the SPSS Statistics 17.0.0 package (SPSS Inc., Chicago, IL, USA).
Results
Patients with ES
A total of 42 patients developed non-infectious fever and one or more clinical signs of ES within 7 days of engraftment. A single patient presented clinical signs of ES without fever, but was being treated with corticosteroids owing to a bronchospasm that evolved to pulmonary infiltrates and hypoxemia 2 days later. The clinical and biological data compatible with ES in these 43 patients are listed in Table 3 .
In all, 41patients (95%) fulfilled the MC and 22 (51%) the SC. The previously mentioned patient without fever only fulfilled SC. An additional patient fulfilled neither the MC nor the SC and consequently was excluded from the rest of our analysis. When comparing the 20 patients with ES according to the MC that did not fulfill the SC, we observed that: 10 (24%) patients had only fever and skin rash, seven (17%) fever and diarrhea and four (10%) developed clinical manifestations at 5-7 days after engraftment. It is noteworthy that these four patients had a very slow engraftment. As diarrhea in the context of auto-SCT can have multiple origins, we carefully checked these seven cases with only fever and diarrhea. In all of them, diarrhea appeared late after conditioning at the same time as the high fever and at the time that the first neutrophils appeared in peripheral blood. In addition, all of them did not respond to antibiotics, had repeated negative cultures and resolved complete and definitively with corticosteroids. Table 1 shows the incidence of ES in the different subgroups of patients.
C-reactive protein (CRP)
All patients with ES had high, and many of them extremely high, serum levels of CRP. All patients in the series had moderate increases in CRP values (mean ± s.d.: 6.4 ± 6.2 mg per 100 ml) when developing a neutropenic fever. This value was similar in patients who later developed ES and in those who did not (6.9±6.4 vs 6.4±5.0 mg per 100 ml). All patients with ES had a sudden increase in CRP values Bilirubin X2 mg per 100 ml or ASAT/ALAT X2 times or creatinine X2 times normal. g If unexplained by other causes. h The original phraseology '24 h before or after' is confusing and has generated incorrect interpretations in some papers (clarified by consultation with the researcher). Figure 1) . CRP values presented during neutropenic fever were a median of three times (range 2-30) lower than those observed in the same patient when ES developed. After steroid treatment, CRP levels quickly returned to normal values in all cases except in one patient who died because of this complication. To evaluate the best value of CRP to discriminate patients with or without ES, we performed a receiver operating characteristic analysis. This analysis showed that a cutoff of 6 mg per 100 ml had the best sensitivity (90%) and specificity (90%) (Figure 2 ).
Evolution
All patients were treated with methylprednisolone (1 mg/kg per 12 h) when ES was suspected. All but one patient had a satisfactory course with rapid resolution of all the symptoms and signs, with their being discharged at a mean of 10.1 days (s.d.±5.6) after ES diagnosis. One patient with scleromyxedema progressed to a multi-organ failure syndrome, despite the steroid treatment, and died 10 days after the diagnosis of ES. Methylprednisolone was administered for 3 days and then rapidly tapered over 7-8 days, although in five patients it was necessary to increase the dose and to prolong the treatment because fever and skin rash reappeared. In no case was graft failure observed.
Incidence of ES and risk factors ES incidence for the whole series was 12.8%. 
Discussion
Engraftment syndrome is an increasingly recognized complication in patients who receive auto-SCT. There is no clear explanation for this increasing incidence. Some reports indicated that the use of PBSCs, higher numbers of CD34 þ cells and the systematic use of G-CSF in the autologous setting, could favor its development. 1, 3, 4, 10 However, these changes were introduced more than a decade ago and do not explain the higher incidence of ES observed in some series in the past few years. 6, 7 The publication 9 years ago of the Spitzer and in 2003 of the Maiolino diagnostic criteria may have favored the recognition and correct diagnosis of this syndrome. 4, 8 Both clinical criteria are very similar and consistent for the three most relevant symptoms and signs of this syndrome: noninfectious fever, skin rash and pulmonary infiltrates with hypoxemia. However, the SC accept the possibility of establishing this diagnosis in a patient without fever, a symptom that is considered the hallmark in the MC. In our series, a well-tolerated high fever was present in all cases. In addition, the SC do not accept patients with only fever and skin rash (33% of patients in our series) or with diarrhea, a symptom that is observed in 40% of our patients, consistent with other series. 8, 10 In addition, the MC accept the diagnosis of ES from 24 h before to any time after the appearance of the first neutrophils in peripheral blood, whereas the SC limits this diagnosis to 96 h around engraftment. Dispenzieri et al., 7 when evaluating auto-SCT for POEMS syndrome, observed that the usefulness of the MC and the SC could be notably improved by increasing the observation time around engraftment. This was true for the SC but not for the MC in our study. The observation of Dispenzieri et al. for the MC was the consequence of an incorrect interpretation of these criteria (aspect consulted with Engraftment syndrome in auto-SCTDr Maiolino). In our opinion, because the dynamic of the engraftment is very variable from patient to patient, the Maiolino approach is more realistic and, additionally, easy to apply. It is not surprising that CRP increases during an inflammatory process similar to ES. 11, 12 However, our observation shows an excellent correlation between CRP levels and ES. When we reviewed CRP levels in the whole series, values as high as that those observed in ES were only observed in patients with severe bacterial or fungal sepsis. Therefore, CRP level can be a useful tool for establishing a correct differential diagnosis in patients with possible ES.
In addition to stem cell source, 1 use of G-CSF, 1 and number of CD34 þ cells 1, 10, 13 as previously mentioned, many other factors have been related to development of ES, including female sex, 14 the underlying disease (higher incidence in solid tumors 2, 8, 13, 14 or autoimmune diseases 6 ), number of therapies before SCT, 2,13 early phases of disease 13 or rate of engraftment. 14 Univariate analysis confirmed a higher incidence of ES in recent years, in women and in those receiving auto-SCT for amyloidosis, conditioned with melphalan, or without previous treatment. We thought that some of these variables would be redundant because the program of auto-SCT for treatment of amyloidosis and POEMS syndrome has grown notably in the recent years and most of these patients have no previous chemotherapy treatment and were conditioned with melphalan. However, multivariate analysis maintained independent significance for female sex and the absence of previous treatment. Despite being previously described, 14 we found no reasonable explanation for the higher incidence of ES observed among females. Several researchers have reported a high incidence of ES among SCTs performed to treat POEMS syndrome and autoimmune diseases. 6, 7 However, none of these reports correlated this observation with the fact that usually these patients do not receive chemotherapy before transplantation. Similarly, a high incidence of ES was observed among patients with breast cancer who receive an SCT. 2, 14 These patients receive less intensive chemotherapies and conditioning than patients with hematological malignancies. In one of these series, 2 the researchers found a clear correlation between ES and the number of previous treatment regimens. Finally, in our series there is a clear negative correlation between intensity of the conditioning and incidence of ES. All these observations seem to indicate that less damaged stem cells, endothelial cells and tissues are able to release more pro-inflammatory cytokines at the time of engraftment, facilitating the development of this syndrome.
In summary, ES is increasingly observed after auto-SCT, probably as a consequence of the inclusion of patients with diseases that have not received intensive chemotherapy before transplantation (autoimmune diseases, POEMS and amyloidosis). Our experience suggests that the Maiolino criteria, when correctly applied, and despite being less specific than the criteria described by Spitzer, permit the detection of all cases with a possible ES. If the fever does not respond to antibiotics, cultures are negative and we detect a sudden increase in CRP values, we have enough evidence to establish the diagnosis and to start the appropriate therapy. Engraftment syndrome in auto-SCT
